January 20, 2020

Dear Sirs,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

‘Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States’

Thanks & Regards,

For Strides Pharma Science Limited

Manjula Ramamurthy
Company Secretary

Encl: As Above
Press Release
January 20, 2020

Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States

January 20, 2020: Strides Pharma Science Limited (Strides) today announced that its step down subsidiary, Strides Pharma Inc. (SPI), has received an Establishment Inspection Report (EIR) from the USFDA for its facility in Riviera Beach, Florida, US. The EIR was issued as an outcome of the USFDA’s inspection of the facility in December 2019. This facility is one of the very few manufacturing facilities in the US with a soft gel capsule(SGC) manufacturing suite for formulations with containment needs.

Strides is one of the global leaders in Rx SGC with a vast portfolio of approved SGCs in the US and other regulated markets. The inspection outcome will bolster the company’s fast-growing SGC franchise in the US and will also help accelerate our foray into the private label opportunity with “in market for market” products. Strides will kickstart the site transfers of its existing SGC portfolio to the site with immediate effect.

In the future, Strides plans to expand additional dosage format suites at the Florida facility, which will mirror the capabilities of its formulations facility in Singapore and will help the company to tap opportunities under various federal government procurement programs, including procurements administered by the Department of Veterans Affairs (VA).

About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi, and United States-Florida. The Company focuses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badree Komandur</td>
<td>Fortuna PR</td>
</tr>
<tr>
<td>Executive Director - Finance</td>
<td>K Srinivas Reddy: +91 90005 27213</td>
</tr>
<tr>
<td>+91 80 6784 0747</td>
<td><a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
<tr>
<td><strong>Investor Relations:</strong></td>
<td>K Priya: +91 95354 25418</td>
</tr>
<tr>
<td>Kannan. N: +91 98450 54745</td>
<td><a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></td>
</tr>
<tr>
<td>Vikesh Kumar: +91 80 6784 0827</td>
<td></td>
</tr>
<tr>
<td>Sandeep Baid: +91 80 6784 0791</td>
<td></td>
</tr>
<tr>
<td>Email: <a href="mailto:Sandeep.baid@strides.com">Sandeep.baid@strides.com</a></td>
<td></td>
</tr>
</tbody>
</table>

Strides Pharma Science Limited
(Formerly Strides Shasun Limited)
CIN: L24230MH1990PLC057062
Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road, Bangalore – 560 076